TABLE 1.
The details of infliximab before fecal microbiota transplantation.
| Pt | Outcomes of IFX | HBI pre-IFX | Age at IFX (yr) | Duration of disease pre-IFX (yr) | Frequency of IFX infusion | Dose of IFX (≥5 mg/kg) | Perianal disease pre-IFX | Concomitant medications* after initial IFX | Efficacy (1 month) | Maintaining time (mo) | AEs | Time between final IFX and FMT (mo) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PNR | 9 | 30 | 6 | 6 | Yes | Anal fistula | Corticosteroid | No response | 0 | No | 42 |
| 2 | Intolerance | 15 | 22 | 6 | 2 | Yes | None | EEN | Response | 2 | Yes | 1 |
| 3 | SLOR | 7 | 24 | 6 | 9 | Yes | Anal fistula | AZA | Remission | 13 | No | 36 |
| 4 | Intolerance | 5 | 23 | 1 | 6 | Yes | None | AZA | Remission | 9 | Yes | 12 |
| 5 | Intolerance | 25 | 24 | 1 | 2 | Yes | None | Corticosteroid/EEN | No response | 0 | Yes | 12 |
| 6 | SLOR | 7 | 18 | 8 | 6 | No | None | Corticosteroid/EEN | No response | 0 | Yes | 90 |
| 7 | Intolerance | 5 | 34 | 1 | 3 | Yes | Abscess | Corticosteroid | Remission | 1 | Yes | 1 |
| 8 | SLOR | 11 | 22 | 6 | 6 | Yes | None | Corticosteroid | No response | 0 | No | 12 |
| 9 | Intolerance | 9 | 28 | 1 | 3 | Yes | None | None | No response | 0 | Yes | 1 |
| 10 | PNR | 6 | 46 | 11 | 6 | Yes | Anal fistula | None | No response | 0 | No | 18 |
| 11 | SLOR | 19 | 28 | 1 | 6 | Yes | None | AZA | Remission | 13 | Yes | 90 |
| 12 | SLOR | 15 | 33 | 1 | 4 | Yes | None | None | Remission | 4 | No | 12 |
| 13 | SLOR | 15 | 30 | 7 | 15 | Yes | Anal fistula | AZA | Remission | 24 | No | 24 |
| 14 | SLOR | 11 | 34 | 18 | 9 | No | Anal fistula | None | Remission | 13 | Yes | 18 |
| 15 | PNR | 9 | 24 | 7 | 9 | No | None | AZA | No response | 0 | No | 12 |
| 16 | SLOR | 5 | 43 | 8 | 14 | No | None | None | Remission | 22 | Yes | 24 |
| 17 | Intolerance | 13 | 14 | 2 | 6 | Yes | None | None | No response | 0 | Yes | 1 |
| 18 | PNR | 8 | 15 | 1 | 15 | Yes | None | None | No response | 0 | No | 2 |
| 19 | Intolerance | 12 | 19 | 1 | 2 | Yes | Anal fistula | None | Remission | 7 | Yes | 7 |
| 20 | PNR | 6 | 12 | 1 | 4 | No | None | None | No response | 0 | No | 6 |
| 21 | SLOR | 6 | 37 | 4 | 5 | Yes | None | None | Remission | 25 | No | 24 |
| 22 | SLOR | 11 | 32 | 8 | 10 | Yes | Anal fistula | AZA | Response | 15 | No | 18 |
| 23 | SLOR | 13 | 20 | 1 | 8 | Yes | None | None | Remission | 11 | No | 48 |
| 24 | Intolerance | 5 | 23 | 1 | 6 | Yes | None | None | Remission | 7 | Yes | 6 |
| 25 | SLOR | 9 | 28 | 2 | 9 | Yes | None | None | Remission | 13 | No | 12 |
| 26 | SLOR | 12 | 39 | 9 | 8 | Yes | None | None | Response | 11 | No | 12 |
| 27 | SLOR | 6 | 26 | 1 | 6 | Yes | Anal fistula | None | Remission | 7 | Yes | 6 |
| 28 | SLOR | 9 | 28 | 6 | 6 | Yes | Anal fistula | AZA | Remission | 10 | No | 12 |
| 29 | Intolerance | 5 | 39 | 7 | 15 | Yes | None | None | Remission | 24 | Yes | 24 |
| 30 | SLOR | 15 | 25 | 1 | 19 | Yes | None | AZA | Remission | 31 | No | 6 |
| 31 | Intolerance | 13 | 34 | 6 | 6 | No | None | None | No response | 0 | Yes | 36 |
| 32 | SLOR | 15 | 31 | 8 | 10 | No | None | None | Remission | 39 | No | 48 |
| # | NA | 9.0 (6.0–13.0) | 28.0 (22.3–33.8) | 6.0 (1.0–8.0) | 6.0 (5.3–9.0) | NA | NA | NA | NA | 7.0 (0–13) | NA | 12.0 (6.0–24.0) |
Pt, patients; IFX, infliximab; HBI, Harvey-Bradshaw index; *5-ASA was the concomitant medications after initial IFX in 75% (24/32) of patients; mo, month; AEs, adverse events; FMT, fecal microbiota transplantation; PNR, primary non-response; SLOR, secondary lose of response; EEN, exclusive enteral nutrition; AZA, azathioprine; Line #, median (IQR); NA, not applicable.